Oppenheimer raised the firm’s price target on Pennant Group to $34 from $28 and keeps an Outperform rating on the shares. The Pennant story remains compelling due to an attractive M&A pipeline and a portfolio that allows for meaningful contributions from “singles” and “doubles” transactions, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG:
- Pennant Group sees FY24 adjusted EPS 89c-95c, consensus 89c
- Pennant Group reports Q2 adjusted EPS 24c, consensus 21c
- Pennant Group files automatic mixed securities shelf
- Pennant Group Enhances Investor Relations with Presentation Update
- Pennant Completes Acquisition of Signature Healthcare at Home’s Washington and Idaho Assets